Current Hepatitis Reports

, Volume 12, Issue 1, pp 59–65 | Cite as

Alcoholic Hepatitis: Steroids vs. Pentoxifylline

  • Laura Smart
  • Leila Gobejishvili
  • Neil Crittenden
  • Shirish Barve
  • Craig J. McClain
Complex Clinical Issues (SA Harrison and NS Reau, Section Editors)

Abstract

Alcoholic hepatitis (AH) remains a major cause of liver-related morbidity and mortality in the United States and is actually increasing in certain areas of Europe. Thus, there is a pressing need for new therapies/approaches. Major barriers for reducing morbidity, mortality, and costs of care include: lack of translational animal and human studies of new therapies for AH; limited trials of combination therapies in AH targeted at specific disease mechanisms (e.g., gut permeability, cytokines, oxidative stress); limited studies on non-invasive, non-mortality end points; few studies on mechanisms of steroid non-responsiveness; and inadequate prognostic indicators, to name only a few. In spite of these gaps, we have made major advances in understanding mechanisms for AH and appropriate therapies for AH. This article reviews mechanisms and rationale for use of steroids and pentoxifylline in AH and future directions in therapy.

Keywords

Alcoholic hepatitis Steroids Pentoxifylline Steroid resistance 

Notes

Disclosure

No potential conflicts of interest relevant to this article were reported.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    • Liangpunsakul S. Clinical characteristics and mortality of hospitalized alcoholic hepatitis patients in the United States. J Clin Gastroenterol. 2011;45(8):714–9. doi:10.1097/MCG.0b013e3181fdef1d. In-hospital mortality rate for AH remains high in the US, especially in those with infectious complications, hepatic encephalopathy, coagulopathy, and acute renal failure. Average length of stay was 6.5 ± 7.y days and average hospital charges were $37,769.PubMedCrossRefGoogle Scholar
  2. 2.
    Sandahl TD, Jepsen P, Thomsen KL, Vilstrup H. Incidence and mortality of alcoholic hepatitis in Denmark 1999–2008: a nationwide population based cohort study. J Hepatol. 2011;54(4):760–4. doi:10.1016/j.jhep.2010.07.016.PubMedCrossRefGoogle Scholar
  3. 3.
    Chedid A, Mendenhall CL, Gartside P, French SW, Chen T, Rabin L. Prognostic factors in alcoholic liver disease. VA Cooperative Study Group. Am J Gastroenterol. 1991;86(2):210–6.PubMedGoogle Scholar
  4. 4.
    Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119(6):1637–48.PubMedCrossRefGoogle Scholar
  5. 5.
    De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. WJG. 2009;15(13):1613–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Gobejishvili L, Crittenden N, McClain C. Controversies in hepatology: the experts analyze both sides. Thorofare: Slack; 2011. p. 3–10.Google Scholar
  7. 7.
    De Bosscher K, Haegeman G. Minireview: latest perspectives on antiinflammatory actions of glucocorticoids. Mol Endocrinol. 2009;23(3):281–91. doi:10.1210/me.2008-0283.PubMedCrossRefGoogle Scholar
  8. 8.
    Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet. 2009;373(9678):1905–17. doi:10.1016/S0140-6736(09)60326-3.PubMedCrossRefGoogle Scholar
  9. 9.
    Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol. 2006;117(3):522–43. doi:10.1016/j.jaci.2006.01.032.PubMedCrossRefGoogle Scholar
  10. 10.
    Maddrey WC, Boitnott JK, Bedine MS, Weber Jr FL, Mezey E, White Jr RI. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978;75(2):193–9.PubMedGoogle Scholar
  11. 11.
    • Mathurin P, O'Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011;60(2):255–60. doi:10.1136/gut.2010.224097. Analysis of individual data from five RCTs showed that corticosteroids significantly improve 28-day survival in patients with severe alcoholic hepatitis. The survival benefit is mainly observed inpatients classified as responders by the Lille model.PubMedCrossRefGoogle Scholar
  12. 12.
    Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis–a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Therapeut. 2008;27(12):1167–78. doi:10.1111/j.1365-2036.2008.03685.x.CrossRefGoogle Scholar
  13. 13.
    Mathurin P, Abdelnour M, Ramond MJ, Carbonell N, Fartoux L, Serfaty L, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology. 2003;38(6):1363–9. doi:10.1016/j.hep.2003.09.038.PubMedGoogle Scholar
  14. 14.
    Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007;45(6):1348–54. doi:10.1002/hep.21607.PubMedCrossRefGoogle Scholar
  15. 15.
    Ito K, Yamamura S, Essilfie-Quaye S, Cosio B, Ito M, Barnes PJ, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med. 2006;203(1):7–13. doi:10.1084/jem.20050466.PubMedCrossRefGoogle Scholar
  16. 16.
    Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005;352(19):1967–76. doi:10.1056/NEJMoa041892.PubMedCrossRefGoogle Scholar
  17. 17.
    Wang FF, Zhu LA, Zou YQ, Zheng H, Wilson A, Yang CD, et al. New insights into the role and mechanism of macrophage migration inhibitory factor in steroid-resistant patients with systemic lupus erythematosus. Arthritis Res Ther. 2012;14(3):R103. doi:10.1186/ar3828.PubMedCrossRefGoogle Scholar
  18. 18.
    • di Mambro AJ, Parker R, McCune A, Gordon F, Dayan CM, Collins P. In vitro steroid resistance correlates with outcome in severe alcoholic hepatitis. Hepatology. 2011;53(4):1316–22. doi:10.1002/hep.24159. Clinical outcome of steroid therapy in an AH patient cohort correlated with in vitro steroid resistance and IL-2 blockade improved in vitro steroid sensitivity. Thus, intrinsic lack of steroid sensitivity may contribute to poor clinical response to steroids in severe AH and IL-2 receptor blocade may represent a possible intervention.PubMedCrossRefGoogle Scholar
  19. 19.
    • Barnes PJ. Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol. 2010;120(2–3):76–85. doi:10.1016/j.jsbmb.2010.02.018. Excellent review of mechanisms and resistance in glucocorticoid control of inflammation. New concepts in resistance including epigenetics are covered.PubMedCrossRefGoogle Scholar
  20. 20.
    Rajendrasozhan S, Yang SR, Edirisinghe I, Yao H, Adenuga D, Rahman I. Deacetylases and NF-kappaB in redox regulation of cigarette smoke-induced lung inflammation: epigenetics in pathogenesis of COPD. Antioxid Redox Signal. 2008;10(4):799–811. doi:10.1089/ars.2007.1938.PubMedCrossRefGoogle Scholar
  21. 21.
    Rogatsky I, Ivashkiv LB. Glucocorticoid modulation of cytokine signaling. Tissue Antigens. 2006;68(1):1–12. doi:10.1111/j.1399-0039.2006.00599.x.PubMedCrossRefGoogle Scholar
  22. 22.
    Hearing SD, Norman M, Probert CS, Haslam N, Dayan CM. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut. 1999;45(3):382–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Kendrick SF, Henderson E, Palmer J, Jones DE, Day CP. Theophylline improves steroid sensitivity in acute alcoholic hepatitis. Hepatology. 2010;52(1):126–31. doi:10.1002/hep.23666.PubMedCrossRefGoogle Scholar
  24. 24.
    Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med. 1990;113(4):299–307.PubMedGoogle Scholar
  25. 25.
    Louvet A, Wartel F, Castel H, Dharancy S, Hollebecque A, Canva-Delcambre V, et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology. 2009;137(2):541–8. doi:10.1053/j.gastro.2009.04.062.PubMedCrossRefGoogle Scholar
  26. 26.
    Louvet A, Diaz E, Dharancy S, Coevoet H, Texier F, Thevenot T, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol. 2008;48(3):465–70. doi:10.1016/j.jhep.2007.10.010.PubMedCrossRefGoogle Scholar
  27. 27.
    Loguercio C, Federico A. Oxidative stress in viral and alcoholic hepatitis. Free Radic Biol Med. 2003;34(1):1–10.PubMedCrossRefGoogle Scholar
  28. 28.
    Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O'Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis–a randomised clinical trial. J Hepatol. 2006;44(4):784–90. doi:10.1016/j.jhep.2005.11.039.PubMedCrossRefGoogle Scholar
  29. 29.
    Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011;365(19):1781–9. doi:10.1056/NEJMoa1101214.PubMedCrossRefGoogle Scholar
  30. 30.
    • Sidhu SS, Goyal O, Singla P, Gupta D, Sood A, Chhina RS, et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Dig Dis Sci. 2012;57(6):1664–71. doi:10.1007/s10620-012-2097-4. This relatively small study (70 subjects) compared the efficacy of corticosteroids plus pentoxifylline with that of corticosteroids alone in improving survival of severe AH patients. Somewhat surprisingly, combination therapy showed no significant survival advantage, and results of larger trials are awaited.PubMedCrossRefGoogle Scholar
  31. 31.
    McClain CJ, Cohen DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology. 1989;9(3):349–51.PubMedCrossRefGoogle Scholar
  32. 32.
    Gobejishvili L, Barve S, Joshi-Barve S, Uriarte S, Song Z, McClain C. Chronic ethanol-mediated decrease in cAMP primes macrophages to enhanced LPS-inducible NF-kappaB activity and TNF expression: relevance to alcoholic liver disease. Am J Gastrointest Liver Physiol. 2006;291(4):G681–8. doi:10.1152/ajpgi.00098.2006.CrossRefGoogle Scholar
  33. 33.
    Taguchi I, Oka K, Kitamura K, Sugiura M, Oku A, Matsumoto M. Protection by a cyclic AMP-specific phosphodiesterase inhibitor, rolipram, and dibutyryl cyclic AMP against Propionibacterium acnes and lipopolysaccharide-induced mouse hepatitis. Inflamm Res Off J Eur Histamine Res Soc [et al]. 1999;48(7):380–5.Google Scholar
  34. 34.
    Gouillon ZQ, Miyamoto K, Donohue TM, Wan YJ, French BA, Nagao Y, et al. Role of CYP2E1 in the pathogenesis of alcoholic liver disease: modifications by cAMP and ubiquitin-proteasome pathway. FBS. 1999;4:A16–25.PubMedGoogle Scholar
  35. 35.
    Diamond I, Wrubel B, Estrin W, Gordon A. Basal and adenosine receptor-stimulated levels of cAMP are reduced in lymphocytes from alcoholic patients. Proc Natl Acad Sci U S A. 1987;84(5):1413–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Nagy LE, Diamond I, Gordon A. Cultured lymphocytes from alcoholic subjects have altered cAMP signal transduction. Proc Natl Acad Sci U S A. 1988;85(18):6973–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Risoe PK, Wang Y, Stuestol JF, Aasen AO, Wang JE, Dahle MK. Lipopolysaccharide attenuates mRNA levels of several adenylyl cyclase isoforms in vivo. Biochim Biophys Acta. 2007;1772(1):32–9. doi:10.1016/j.bbadis.2006.08.007.PubMedCrossRefGoogle Scholar
  38. 38.
    Jin SL, Lan L, Zoudilova M, Conti M. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol. 2005;175(3):1523–31.PubMedGoogle Scholar
  39. 39.
    Gobejishvili L, Barve S, Joshi-Barve S, McClain C. Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol. 2008;295(4):G718–24. doi:10.1152/ajpgi.90232.2008.PubMedCrossRefGoogle Scholar
  40. 40.
    Whitfield K, Rambaldi A, Wetterslev J, Gluud C. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev. 2009(4):CD007339. doi:10.1002/14651858.CD007339.pub2.
  41. 41.
    Lebrec D, Thabut D, Oberti F, Perarnau JM, Condat B, Barraud H, et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology. 2010;138(5):1755–62. doi:10.1053/j.gastro.2010.01.040.PubMedCrossRefGoogle Scholar
  42. 42.
    Tyagi P, Sharma P, Sharma BC, Puri AS, Kumar A, Sarin SK. Prevention of hepatorenal syndrome in patients with cirrhosis and ascites: a pilot randomized control trial between pentoxifylline and placebo. Eur J Gastroenterol Hepatol. 2011;23(3):210–7. doi:10.1097/MEG.0b013e3283435d76.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Laura Smart
    • 1
    • 3
    • 6
  • Leila Gobejishvili
    • 1
    • 2
    • 3
    • 7
  • Neil Crittenden
    • 3
    • 6
  • Shirish Barve
    • 1
    • 2
    • 3
    • 4
    • 8
  • Craig J. McClain
    • 1
    • 2
    • 3
    • 4
    • 5
    • 9
  1. 1.Division of Gastroenterology, Hepatology and NutritionUniversity of Louisville School of MedicineLouisvilleUSA
  2. 2.UofL Alcohol Research CenterUniversity of Louisville School of MedicineLouisvilleUSA
  3. 3.Department of MedicineUniversity of Louisville School of MedicineLouisvilleUSA
  4. 4.Department of Pharmacology & ToxicologyUniversity of Louisville School of MedicineLouisvilleUSA
  5. 5.Robely Rex Veterans Affairs Medical CenterLouisvilleUSA
  6. 6.University of LouisvilleLouisvilleUSA
  7. 7.University of LouisvilleLouisvilleUSA
  8. 8.University of LouisvilleLouisvilleUSA
  9. 9.University of LouisvilleLouisvilleUSA

Personalised recommendations